Recently, novel glucose-lowering agents (GLAs), namely glucagon-like peptide-1 receptor agonists (GLP-1RAs) [11–13] and sodium-glucose cotransporter 2 inhibitors (SGLT2is) [14, 15], were shown to improve liver fibrosis-related biomarkers such as alanine aminotransferase (ALT), visceral adipose tissue volume, and liver fat content. The gene discussed is GPT; the disease is Hepatic fibrosis.